A new collaboration between Lucent Diagnostics and Tempus AI aims to improve detection accuracy and access to testing for patients with Alzheimer’s disease.
Lucent Diagnostics, a brand of Quanterix Corp, and Tempus AI Inc have announced a collaboration to integrate blood-based Alzheimer’s biomarker testing into clinical workflows. The agreement is designed to broaden access to a multi-biomarker panel to improve detection accuracy for the disease.
Through the partnership, Tempus AI will develop a care gap program for Alzheimer’s disease blood-based biomarker testing via Tempus Next, an artificial intelligence (AI)-enabled care pathway intelligence platform. The LucentAD Complete multi-biomarker blood test will also become available for neurologists to order through the Tempus clinical ordering platform.
Addressing the Care Gap
According to the companies, more than 7 million Americans currently live with Alzheimer’s disease, but only a small portion are evaluated for eligibility for approved treatments. The collaboration aims to address this gap by embedding clinical guideline-directed identification, blood-based biomarker testing options, and clinical decision-making workflows directly into the tools used by neurologists.
“This collaboration represents an important step toward ensuring blood-based Alzheimer’s biomarker testing becomes part of routine clinical practice—without placing additional burden on providers,” says Everett Cunningham, CEO of Quanterix, in a release. “By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies.”
Workflow Integration
Tempus Next identifies care gaps and provides actionable insights to clinicians at the point of care. While the care gap program helps identify patients who may benefit from testing based on established clinical guidelines, clinicians have the option to order the LucentAD Complete test through existing electronic health record integrations.
The collaboration focuses on streamlining the diagnostic journey to support earlier clinical decisions through high-sensitivity biomarker innovation, according to the companies.
ID 294234505 © Skypixel | Dreamstime.com
